Trial NCT03386721

View at ClinicalTrials.gov 
Org. Study IDs: BP40234
Secondary IDs: 2017-003182-94

Last trial update was posted on 2023-02-21

MeSH Interventions

Antibodies Atezolizumab Gemcitabine Vinorelbine

MeSH Conditions

Uterine Cervical Neoplasms

Other Conditions

Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers

Stopping Reasons

The Sponsor discontinued the development of Simlukafusp alfa due to portfolio prioritization, not due to any safety, efficacy, or quality issues.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID